4.8 Article

Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System

Journal

HEPATOLOGY
Volume 73, Issue 6, Pages 2311-2325

Publisher

WILEY
DOI: 10.1002/hep.31598

Keywords

-

Ask authors/readers for more resources

This study aimed to assess the survival of intrahepatic cholangiocarcinoma with liver metastases compared to other early stages and propose a modified version of AJCC staging that includes liver metastases as a separate stage. Results showed that iCCA with liver metastases had a worse outcome compared to other early stages, suggesting the need for a modification to AJCC staging to better reflect this difference.
Background and Aims Intrahepatic cholangiocarcinoma (iCCA) with liver metastases is perceived to have a poor prognosis, but the American Joint Committee on Cancer (AJCC) classifies them as early stage in the absence of lymph nodes or extrahepatic spread. Approach and Results Patients with iCCA from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) and Surveillance, Epidemiology, and End Results (SEER) registries with survival/staging (AJCC v.7) data were eligible. Modified staging was used (mAJCC v.7): group A: stages I-III (excluding T2bN0); group B: stage IVa (excluding T2bN1M0); group C: liver metastases (T2bN0/1); and group D: stage IVb (extrahepatic metastases). Survival analysis (Kaplan-Meier and Cox regression) was performed in an ENS-CCA training cohort (TC) and findings internally (ENS-CCA iVC) and externally (SEER) validated. The aim was to assess whether liver metastases (group C) had a shorter survival compared to other early stages (group A) to propose a modified version of AJCC v.8 (mAJCC v.8). A total of 574 and 4,171 patients from the ENS-CCA and SEER registries were included. Following the new classification, 19.86% and 17.31% of patients from the ENS-CCA and SEER registries were reclassified into group C, respectively. In the ENS-CCA TC, multivariable Cox regression was adjusted for obesity (p = 0.026) and performance status (P < 0.001); patients in group C (HR, 2.53; 95% CI, 1.18-5.42; P = 0.017) had a higher risk of death (vs. group A). Findings were validated in the ENS-CCA iVC (HR, 2.93; 95% CI, 2.04-4.19; P < 0.001) and in the SEER registry (HR, 1.88; 95% CI, 1.68-2.09; P < 0.001). Conclusions iCCA with liver metastases has a worse outcome than other early stages of iCCA. Given that AJCC v.8 does not take this into consideration, a modification of AJCC v.8 (mAJCC v.8), including liver metastases: multiple liver lesions, with or without vascular invasion as an M1a stage, is suggested.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemistry & Molecular Biology

Mitochondrial RNA methyltransferase TRMT61B is a new, potential biomarker and therapeutic target for highly aneuploid cancers

Alberto Martin, Carolina Epifano, Borja Vilaplana-Marti, Ivan Hernandez, Rocio I. R. Macias, Angel Martinez-Ramirez, Ana Cerezo, Pablo Cabezas-Sainz, Maria Garranzo-Asensio, Sandra Amarilla-Quintana, Deborah Gomez-Dominguez, Eduardo Caleiras, Jordi Camps, Gonzalo Gomez-Lopez, Marta Gomez de Cedron, Ana Ramirez de Molina, Rodrigo Barderas, Laura Sanchez, Susana Velasco-Miguel, Ignacio Perez de Castro

Summary: Despite being frequently observed in cancer cells, chromosomal instability (CIN) and aneuploidy have adverse effects on cellular homeostasis. Epitranscriptomic marks catalyzed by RNA-modifying enzymes change under stress, but their association with aneuploidy is still unknown. TRMT61B, a mitochondrial RNA methyltransferase enzyme, is found to be associated with high levels of aneuploidy in cancer cells. Depletion of TRMT61B induces senescence in cells with low aneuploidy, and apoptosis in cells with high aneuploidy. These findings suggest TRMT61B as a potential biomarker for targeting highly aneuploid tumors.

CELL DEATH AND DIFFERENTIATION (2023)

Article Gastroenterology & Hepatology

Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study

Stephan Buch, Hamish Innes, Philipp Ludwig Lutz, Hans Dieter Nischalke, Jens U. Marquardt, Janett Fischer, Karl Heinz Weiss, Jonas Rosendahl, Astrid Marot, Marcin Krawczyk, Markus Casper, Frank Lammert, Florian Eyer, Arndt Vogel, Silke Marhenke, Johann von Felden, Rohini Sharma, Stephen Rahul Atkinson, Andrew McQuillin, Jacob Nattermann, Clemens Schafmayer, Andre Franke, Christian Strassburg, Marcella Rietschel, Heidi Altmann, Stefan Sulk, Veera Raghavan Thangapandi, Mario Brosch, Carolin Lackner, Rudolf E. Stauber, Ali Canbay, Alexander Link, Thomas Reiberger, Mattias Mandorfer, Georg Semmler, Bernhard Scheiner, Christian Datz, Stefano Romeo, Stefano Ginanni Corradini, William Lucien Irving, Joanne R. Morling, Indra Neil Guha, Eleanor Barnes, M. Azim Ansari, Jocelyn Quistrebert, Luca Valenti, Sacha A. Mueller, Marsha Yvonne Morgan, Jean-Francois Dufour, Jonel Trebicka, Thomas Berg, Pierre Deltenre, Sebastian Mueller, Jochen Hampe, Felix Stickel

Summary: This study identifies rs2242652 in TERT as a novel protective factor for HCC in patients with alcohol-related cirrhosis.
Article Gastroenterology & Hepatology

Human duodenal submucosal glands contain a defined stem/progenitor subpopulation with liver-specific regenerative potential

Vincenzo Cardinale, Guido Carpino, Diletta Overi, Samira Safarikia, Wencheng Zhang, Matt Kanke, Antonio Franchitto, Daniele Costantini, Olga Riccioni, Lorenzo Nevi, Michele Chiappetta, Paolo Onori, Matteo Franchitto, Simone Bini, Yu-Han Hung, Quirino Lai, Ilaria Zizzari, Marianna Nuti, Carmine Nicoletti, Saula Checquolo, Laura Di Magno, Maria Valeria Giuli, Massimo Rossi, Praveen Sethupathy, Lola M. Reid, Domenico Alvaro, Eugenio Gaudio

Summary: Stem/progenitor cells with regenerative potential have been identified in the adult human duodenum. These cells can form organoids in vitro and differentiate into mature liver cells in vivo. The duodenal submucosal gland cells could potentially serve as a novel cell source for regenerative medicine of the liver.

JOURNAL OF HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma

Joachim Merters, Angela Lamarca

Summary: Management of biliary tract cancers (BTCs) is evolving rapidly. Chemotherapy with cisplatin and gemcitabine (with durvalumab) followed by second-line FOLFOX is the cornerstone of treatment for advanced BTC. Targeted therapies for specific genetic mutations have brought precision medicine to the forefront, and immunotherapy combined with chemotherapy has shown promising activity. The field is now exploring combination strategies to enhance therapeutic responses. This review focuses on the rationale for these combinations and summarizes current clinical trial data.

JOURNAL OF HEPATOLOGY (2023)

Review Cell Biology

The Landscape of HNF1B Deficiency: A Syndrome Not Yet Fully Explored

Alessandro Gambella, Silvia Kalantari, Massimiliano Cadamuro, Marco Quaglia, Maurizio Delvecchio, Luca Fabris, Michele Pinon

Summary: The hepatocyte nuclear factor 1 beta (HNF1B) gene plays a crucial role in the development of specialized epithelia in various organs during embryogenesis. Pathogenic variants of HNF1B have been associated with a complex syndrome that mainly affects children, leading to diabetes and renal complications. However, recent studies have highlighted the importance of liver involvement, including a potential link to tumor development, expanding the understanding of HNF1B-associated disease. This review aims to provide a comprehensive analysis of the genetic, phenotypic, and clinical features of HNF1B deficiency in both pediatric and adult populations.

CELLS (2023)

Article Nutrition & Dietetics

Practical guideline on obesity care in patients with gastrointestinal and liver diseases- Joint ESPEN/UEG guideline

Stephan C. Bischoff, Johann Ockenga, Ahad Eshraghian, Rocco Barazzoni, Luca Busetto, Marjo Campmans-Kuijpers, Vincenzo Cardinale, Irit Chermesh, Haluk Tarik Kani, Wafaa Khannoussi, Laurence Lacaze, Miguel Leon-Sanz, Juan M. Mendive, Michael W. Mueller, Frank Tacke, Anders Thorell, Darija Vranesic Bender, Arved Weimann, Cristina Cuerda

Summary: This practical guideline focuses on the diagnosis and treatment of obesity in patients with chronic gastrointestinal diseases, with a particular emphasis on metabolic associated liver disease. The guideline provides evidence-based advice in a condensed format, with 100 recommendations covering a multidisciplinary approach to care.

CLINICAL NUTRITION (2023)

Article Gastroenterology & Hepatology

Serum lipidome unravels a diagnostic potential in bile acid diarrhoea

Monika Lewinska, Martin Lund Karhus, Anne-Marie Gade Ellegaard, Manuel Romero-Gomez, Rocio I. R. Macias, Jesper B. Andersen, Filip Krag Knop

Summary: Scientists developed a blood test-based method for diagnosing bile acid diarrhea (BAD), which showed superior specificity and sensitivity compared with current blood test-based diagnostics.
Article Gastroenterology & Hepatology

Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance

Diego Calvisi, Luke Boulter, Javier Vaquero, Anna Saborowski, Luca M. Fabris, Pedro Rodrigues, Cedric E. Coulouarn, Rui Castro, Oreste Segatto, Chiara Raggi, Luc J. W. van der Laan, Guido Carpino, Benjamin Goeppert, Stephanie J. Roessler, Timothy Kendall, Matthias Evert, Ester W. Gonzalez-Sanchez, Juan Valle, Arndt Vogel, John J. Bridgewater, Mitesh J. Borad, Gregory R. Gores, Lewis Roberts, Jose J. G. B. Marin, Jesper Andersen, Domenico Alvaro, Alejandro M. Forner, Jesus Banales, Vincenzo Cardinale, Rocio I. R. Macias, Silve Vicent, Xin Chen, Chiara Braconi, Monique M. A. Verstegen, Laura Fouassier, Lewis Roberts, Alexander Scheiter, Florin M. Selaru, Katja Evert, Kirsten Utpatel, Laura Broutier, Massimiliano Cadamuro, Meritxell Huch, Robert Goldin, Sergio A. Gradilone, Yoshimasa Saito

Summary: In this Consensus Statement, experts provide recommendations on the criteria for preclinical models of cholangiocarcinoma (CCA) to increase disease understanding and develop novel therapeutic approaches.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2023)

Review Oncology

New Challenges in the Management of Cholangiocarcinoma: The Role of Liver Transplantation, Locoregional Therapies, and Systemic Therapy

Ezequiel Mauro, Joana Ferrer-Fabrega, Tamara Sauri, Alexandre Soler, Amparo Cobo, Marta Burrel, Gemma Iserte, Alejandro Forner

Summary: Cholangiocarcinoma (CCA) is a highly lethal neoplasia with increasing incidence. Although surgical resection is the main treatment, it is only successful in one third of patients and has a high risk of recurrence. Other therapeutic strategies like liver transplantation, locoregional treatments, and new chemotherapy schemes based on immunotherapy or targeted therapies have potential to improve overall survival. However, more collaborative efforts and high-quality studies are needed to investigate their use and applicability.

CANCERS (2023)

Article Gastroenterology & Hepatology

Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma

Ainhoa Lapitz, Mikel Azkargorta, Piotr Milkiewicz, Paula Olaizola, Ekaterina Zhuravleva, Marit M. Grimsrud, Christoph Schramm, Ander Arbelaiz, Colm J. O'Rourke, Adelaida La Casta, Malgorzata Milkiewicz, Tania Pastor, Mette Vesterhus, Raul Jimenez-Aguero, Michael T. Dill, Angela Lamarca, Juan W. Valle, Rocio I. R. Macias, Laura Izquierdo-Sanchez, Ylenia Perez Castano, Francisco Javier Caballero-Camino, Ioana Riano, Marcin Krawczyk, Cesar Ibarra, Javier Bustamante, Luiz M. Nova-Camacho, Juan M. Falcon-Perez, Felix Elortza, Maria J. Perugorria, Jesper B. Andersen, Luis Bujanda, Tom H. Karlsen, Trine Folseraas, Pedro M. Rodrigues, Jesus M. Banales

Summary: Protein biomarkers for the diagnosis and prognosis of cholangiocarcinoma (CCA) were found in serum extracellular vesicles (EVs), providing important information for individuals at high-risk, such as those with primary sclerosing cholangitis (PSC).

JOURNAL OF HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

FXR agonists INT-787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet-induced ob/ob mouse model of NASH

Laura G. Di Pasqua, Marta Cagna, Giuseppina Palladini, Anna C. Croce, Massimiliano Cadamuro, Luca Fabris, Stefano Perlini, Luciano Adorini, Andrea Ferrigno, Mariapia Vairetti

Summary: The effects of two FXR agonists, OCA and INT-787, on hepatic levels of various proteins in a NASH model were compared. The results showed that INT-787 is superior to OCA in controlling specific cell types and clinically relevant anti-inflammatory and antifibrotic molecular mechanisms in NASH.

LIVER INTERNATIONAL (2023)

Article Health Care Sciences & Services

Prognosis Discussion and Referral to Community Palliative Care Services in Patients with Advanced Pancreatic Cancer Treated in a Tertiary Cancer Centre

Sarah Clelland, Christina L. Nuttall, Helen E. Stott, Joseph Cope, Natalie L. Barratt, Kelly Farrell, Manyi V. Eyong, Jack P. Gleeson, Angela Lamarca, Richard A. Hubner, Juan W. Valle, Mairead G. Mcnamara

Summary: This study analyzed the case-notes of newly diagnosed patients with advanced pancreatic cancer and found that approximately two-thirds of cases had documented prognosis discussions. However, there were missed opportunities for prognosis discussions. Nurse clinicians had the highest frequency of prognosis discussion and referral to community palliative care services. Greater attention to documentation of prognosis discussions is recommended.

HEALTHCARE (2023)

Article Gastroenterology & Hepatology

Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma

David J. Pinato, Takahiro Kaneko, Antonio D'Alessio, Alejandro Forner, Petros Fessas, Beatriz Minguez, Edoardo G. Giannini, Federica Grillo, Alba Diaz, Francesco A. Mauri, Claudia A. M. Fulgenzi, Alessia Dalla Pria, Robert D. Goldin, Giulia Pieri, Pierluigi Toniutto, Claudio Avellini, Maria Corina Plaz Torres, Ayse U. Akarca, Teresa Marafioti, Sherrie Bhoori, Jose Maria Miro, Mark Bower, Norbert Brau, Vincenzo Mazzaferro

Summary: The aim of this study was to evaluate the impact of HIV infection on the functional characteristics of T cell infiltrate in hepatocellular carcinoma (HCC). Results showed that HIV infection was associated with increased immune exhaustion and higher expression of PD-L1 in tumor tissue. Therefore, prospective testing of immunotherapy in HIV-associated HCC is warranted.

JHEP REPORTS (2023)

Review Oncology

Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma

Angela Lamarca, Lorena Ostios, Mairead G. Mcnamara, Carlos Garzon, Jack P. Gleeson, Julien Edeline, Ana Herrero, Richard A. Hubner, Victor Moreno, Juan W. Valle

Summary: Precision medicine has had a major impact on the management of advanced cholangiocarcinoma (CCA) patients, with molecular profiling providing new targets for treatment. However, there are still challenges such as lack of response and the development of drug resistance.

CANCER TREATMENT REVIEWS (2023)

No Data Available